CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in two upcoming investor conferences.
- William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present at the Baird 2019 Global Healthcare Conference on Wednesday, September 4, 2019, at 12:15 p.m. EDT. The conference will be held at the InterContinental New York Barclay in New York City.
- William ‘Obi’ Greenman and Kevin D. Green, Cerus’ vice president finance and chief financial officer, are scheduled to present at 17th Annual Morgan Stanley Healthcare Conference on Monday, September 9, 2019, at 1:05 p.m. EDT. The conference will be held at the Grand Hyatt New York in New York City.
Live webcasts of the presentations will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. Replays of the presentations will be available for approximately two weeks following the completion of the events.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Based in Concord, California, our employees are dedicated to deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System, and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. For more information about Cerus, visit www.cerus.com.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
